From the genome to the proteome--biomarkers in colorectal cancer

TY - JOUR

T1 - From the genome to the proteome--biomarkers in colorectal cancer

AU - Habermann, Jens K

AU - Bader, Franz G

AU - Franke, Christian

AU - Zimmermann, Kaja

AU - Gemoll, Timo

AU - Fritzsche, Britta

AU - Ried, Thomas

AU - Auer, Gert

AU - Bruch, Hans-Peter

AU - Roblick, Uwe J

PY - 2008/1

Y1 - 2008/1

N2 - BACKGROUND AND AIMS: Colorectal cancer is the second leading cause of cancer-related death. Current clinical practice in colorectal cancer screening (fecal occult blood test, FOBT; colonoscopy) has contributed to a reduction of mortality. However, despite these screening programs, about 70% of carcinomas are detected at advanced tumor stages (UICC III/IV) presenting poor patient prognosis. Thus, innovative tools and methodologies for early cancer detection can directly result in improving patient survival rates.PATIENTS/METHODS: Biomedical research has advanced rapidly in recent years with the availability of technologies such as global gene and protein expression profiling. Comprehensive tumor profiling has become a field of intensive research aiming at identifying biomarkers relevant for improved diagnostics and therapeutics.RESULTS: In this paper, we report a comprehensive review of genomic, transcriptomic, and proteomic approaches for biomarker identification in tissue and blood with a main emphasis on two-dimensional gel-electrophoresis (2-DE) and mass spectrometry analyses.CONCLUSION: Proteomics-based technologies enable to distinguish the healthy patient from the tumor patient with high sensitivity and specificity and could greatly improve common classification systems and diagnostics. However, this progress has not yet been transferred from bench to bedside but could open the door to a more accurate and target specific personalized medicine with improved patient survival.

AB - BACKGROUND AND AIMS: Colorectal cancer is the second leading cause of cancer-related death. Current clinical practice in colorectal cancer screening (fecal occult blood test, FOBT; colonoscopy) has contributed to a reduction of mortality. However, despite these screening programs, about 70% of carcinomas are detected at advanced tumor stages (UICC III/IV) presenting poor patient prognosis. Thus, innovative tools and methodologies for early cancer detection can directly result in improving patient survival rates.PATIENTS/METHODS: Biomedical research has advanced rapidly in recent years with the availability of technologies such as global gene and protein expression profiling. Comprehensive tumor profiling has become a field of intensive research aiming at identifying biomarkers relevant for improved diagnostics and therapeutics.RESULTS: In this paper, we report a comprehensive review of genomic, transcriptomic, and proteomic approaches for biomarker identification in tissue and blood with a main emphasis on two-dimensional gel-electrophoresis (2-DE) and mass spectrometry analyses.CONCLUSION: Proteomics-based technologies enable to distinguish the healthy patient from the tumor patient with high sensitivity and specificity and could greatly improve common classification systems and diagnostics. However, this progress has not yet been transferred from bench to bedside but could open the door to a more accurate and target specific personalized medicine with improved patient survival.

KW - Aneuploidy

KW - Biomarkers, Tumor

KW - Colorectal Neoplasms

KW - Electrophoresis, Gel, Two-Dimensional

KW - Gene Expression Profiling

KW - Genetic Markers

KW - Genome

KW - Humans

KW - Mass Spectrometry

KW - Neoplasm Staging

KW - Predictive Value of Tests

KW - Protein Array Analysis

KW - Proteome

KW - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

KW - Journal Article

KW - Review

U2 - 10.1007/s00423-007-0230-1

DO - 10.1007/s00423-007-0230-1

M3 - SCORING: Journal article

C2 - 17938952

VL - 393

SP - 93

EP - 104

JO - LANGENBECK ARCH SURG

JF - LANGENBECK ARCH SURG

SN - 1435-2443

IS - 1

ER -